Nikang Therapeutics, Inc.
Clinical trials sponsored by Nikang Therapeutics, Inc., explained in plain language.
-
New drug cocktail for advanced kidney cancer shows early promise, but trial halted
Disease control TerminatedThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:35 UTC
-
Experimental cancer pill tested in 23 patients, study halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:27 UTC
-
New pill shows promise in battling advanced kidney cancer
Disease control TerminatedThis trial tested an oral drug called NKT2152 in 120 people with advanced clear cell kidney cancer that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The study was stopped early, but results may help guide future trea…
Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC